Market news
The latest analyst work on Cryoport points to a higher blended fair value estimate, with price targets moving from US$17.06 to US$19.33, about a 13% uplift in the modeled target level. That shift lines up with more constructive Street commentary, as several bullish analysts highlight Cryoport’s Cell and Gene Therapy logistics and bioservices as key supports for the higher target range. As you read on, you will see how to track these shifting assumptions and what they might mean for your own...
Detailed price information for Cryoport Inc (CYRX-Q) from The Globe and Mail including charting and trades.
CGT services revenue surged 15% as clinical trial support expanded to 779 trials globally.
CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Detailed price information for Cryoport Inc (CYRX-Q) from The Globe and Mail including charting and trades.
Moby summary of Cryoport, Inc.'s Q2 2026 earnings call
CryoPort Inc (CYRX) achieves positive adjusted EBITDA and reaffirms full-year guidance amid strong biostorage growth and expanding commercial therapy support.
CryoPort (NASDAQ:CYRX) reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million. Chief Executive Officer Jerrell Shelton said revenue momentum continue
Motley Fool Press Release.
Cryoport is back in focus after the modeled fair value in one framework moved from US$15.61 to US$17.06, signaling a higher price target being used in recent analysis. That shift lines up with Street research that has taken a more constructive tone on the stock, with higher targets in the mid to high teens and above US$20 tied to what analysts view as healthier trends across MVE, BioLogistics, and BioStorage. Read on to see how these updated targets fit into the evolving Cryoport narrative...
Detailed price information for Intuitive Machines Inc (LUNR-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.